

# Enhanced Annual Drug List Updates

July 2025

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
ADALIMUMAB-ADAZ (adalimumab-adaz soln auto-injector 80 mg/0.8ml)	Brand	Addition, Preferred Status
ADALIMUMAB-ADAZ (adalimumab-adaz soln prefilled syringe 10 mg/0.1ml)	Brand	Addition, Preferred Status
ADALIMUMAB-ADAZ (adalimumab-adaz soln prefilled syringe 20 mg/0.2ml)	Brand	Addition, Preferred Status
ATTRUBY (acoramidis hcl tab pack 356 mg (712 mg twice daily))	Brand	Addition, Preferred Status
CTEXLI (chenodiol tab 250 mg)	Brand	Addition, Preferred Status
EBGLYSS (lebrikizumab-lbkz solution prefilled syringe 250 mg/2ml)	Brand	Addition, Preferred Status
EBGLYSS (lebrikizumab-lbkz subcutaneous soln auto-inject 250 mg/2ml)	Brand	Addition, Preferred Status
ESPEROCT (antihemophilic factor recomb glycopeg-exei for inj 4000 unit)	Brand	Addition, Preferred Status
ITOVEBI (inavolisib tab 3 mg)	Brand	Addition, Preferred Status
ITOVEBI (inavolisib tab 9 mg)	Brand	Addition, Preferred Status
JIVI (antihemophil fact rcmb (bdd-rfviii peg-aucl)for inj 4000 unit)	Brand	Addition, Preferred Status
NEMLUVIO (nemolizumab-ilto for subcutaneous auto-injector 30 mg)	Brand	Addition, Preferred Status
SELARSDI (ustekinumab-aekn soln prefilled syringe 45 mg/0.5ml)	Brand	Addition, Preferred Status
SELARSDI (ustekinumab-aekn soln prefilled syringe 90 mg/ml)	Brand	Addition, Preferred Status
SIMLANDI (adalimumab-ryvk prefilled syringe kit 20 mg/0.2ml)	Brand	Addition, Preferred Status
SIMLANDI (adalimumab-ryvk prefilled syringe kit 80 mg/0.8ml)	Brand	Addition, Preferred Status
SIMLANDI 1-PEN KIT (adalimumab-ryvk auto-injector kit 80 mg/0.8ml)	Brand	Addition, Preferred Status
STEQEYMA (ustekinumab-stba soln prefilled syringe 45 mg/0.5ml)	Brand	Addition, Preferred Status
STEQEYMA (ustekinumab-stba soln prefilled syringe 90 mg/ml)	Brand	Addition, Preferred Status
TREMFYA INDUCTION PACK FOR CROHNS DISEASE (guselkumab soln auto-injector 200 mg/2ml)	Brand	Addition, Preferred Status
TREMFYA PEN (guselkumab soln auto-injector 100 mg/ml)	Brand	Addition, Preferred Status
YESINTEK (ustekinumab-kfce soln prefilled syringe 45 mg/0.5ml)	Brand	Addition, Preferred Status
YESINTEK (ustekinumab-kfce soln prefilled syringe 90 mg/ml)	Brand	Addition, Preferred Status
YESINTEK (ustekinumab-kfce subcutaneous soln 45 mg/0.5ml)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. Prime Therapeutics LLC is a separate company BCBSIL contracts with to provide pharmacy solutions. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.